Manfred Heller

Head of proteomics core facility

University of Bern
Country flagSwitzerland

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (13)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Cryptosporidium parvum is an apicomplexan parasite causing persistent diarrhea in humans and animals. Issuing from target-based drug development, calcium-dependent protein kinase 1 inhibitors, collectively named bumped kinase inhibitors (BKIs), with excellent efficacies in vitro and in vivo have been generated. Some BKIs including BKI-1748 share a core structure with similarities to the first-generation antiprotozoal drug quinine, which is known to exert notorious side effects. Unlike quinine, BKI-1748 rapidly interfered with C. parvum proliferation in the human colon tumor (HCT) cell line HCT-8 cells and caused dramatic effects on the parasite ultrastructure. To identify putative BKI targets in C. parvum and in host cells, we performed differential affinity chromatography with cell-free extracts from non-infected and infected HCT-8 cells using BKI-1748 and quinine epoxy-activated sepharose columns followed by mass spectrometry. C. parvum proteins of interest were identified in eluates from columns coupled to BKI-1748, or in eluates from both BKI-1748 and quinine columns. However, no C. parvum proteins could be identified binding exclusively to BKI-1748. In contrast, 25 BKI-1748-specific binding proteins originating from HCT-8 cells were detected. Moreover, 29 C. parvum and 224 host cell proteins were identified in both BKI-1748 as well as in quinine eluates. In both C. parvum and host cells, the largest subset of binding proteins was involved in RNA binding and modification, with a focus on ribosomal proteins and proteins involved in RNA splicing. These findings extend previous results, showing that BKI-1748 interacts with putative targets involved in common, essential pathways such as translation and RNA processing.

Year:

2024

Year:

2024

Year:

2024

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. The prognosis for patients with high-grade and metastatic disease is still very poor, and survivors are burdened with long-lasting side effects. Therefore, more effective and less toxic therapies are needed. Surface proteins are ideal targets for antibody-based therapies, like bispecific antibodies, antibody-drug conjugates, or chimeric antigen receptor (CAR) T-cells. Specific surface targets for RMS are scarce. Here, we performed a surfaceome profiling based on differential centrifugation enrichment of surface/membrane proteins and detection by LC-MS on six fusion-positive (FP) RMS cell lines, five fusion-negative (FN) RMS cell lines, and three RMS patient-derived xenografts (PDXs). A total of 699 proteins were detected in the three RMS groups. Ranking based on expression levels and comparison to expression in normal MRC-5 fibroblasts and myoblasts, followed by statistical analysis, highlighted known RMS targets such as FGFR4, NCAM1, and CD276/B7-H3, and revealed AGRL2, JAM3, MEGF10, GPC4, CADM2, as potential targets for immunotherapies of RMS. L1CAM expression was investigated in RMS tissues, and strong L1CAM expression was observed in more than 80% of alveolar RMS tumors, making it a practicable target for antibody-based therapies of alveolar RMS.

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (17)

Sabine Kaessmeyer

University of Bern

SWITZERLAND
View details

Thomas Démoulins

Universität Zürich Vetsuisse-Fakultät

SWITZERLAND
View details

Andrew Hemphill

University of Bern

SWITZERLAND
View details

Theresa Maria Wagner

Associate Professor

UiT The Arctic University of Norway

NORWAY
View details

Rössler Jochen

University of Bern

SWITZERLAND
View details

Thatcha Yimthin

University of Bern

SWITZERLAND
View details

Luis Miguel Ortega-Mora

Professor

Universidad Complutense de Madrid

SPAIN
View details

Joachim Müller

University of Bern

SWITZERLAND
View details

Benoît Zuber

Full Professor, co-director

University of Bern

SWITZERLAND
View details

Kayode Ojo

Research Professor

University of Washington

UNITED STATES
View details

Rossitza Irobalieva

ETH Zürich

SWITZERLAND
View details

alice vismarra

University of Parma

ITALY
View details

Wesley Van Voorhis

Professor

University of Washington

UNITED STATES
View details

Michele Bernasconi

Head of Lab Research

Inselspital Universitätsspital Bern

SWITZERLAND
View details

Franco Bisceglie

Associate Professor

University of Parma

ITALY
View details

Joerg Jores

Professor and Director

University of Bern

SWITZERLAND
View details

Britta Lundström-Stadelmann

Professor and Co-Director Institute of Parasitology (60%)

University of Bern

SWITZERLAND
View details